Table 4. SphK/S1p/S1PR drugs in clinical trial.
| Drug | SphK selectivity | Indications | ClinicalTrials.gov identifier | Phase |
|---|---|---|---|---|
| Safingol | Sphingosine derivative, PKC inhibitor |
Solid tumors, combined with fenretinide Solid tumors, combined with cisplatin |
NCT01553071 NCT00084812 |
I [283] I (Completed) |
| ABC294640 | SPHK2 inhibitor | Pancreatic cancer Diffuse Large B Cell Lymphoma Multiple Myeloma Carcinoma, Hepatocellular |
NCT01488513 NCT02229981 NCT02757326 NCT02939807 |
I I Not yet recruiting. Not Yet recruiting. |
| Sonepcizumab (ASONEP) | S1P-specific monoclonal antibody |
Solid tumors Unresectable and Refractory Renal Cell Carcinoma |
NCT00661414 NCT01762033 |
I (Completed) II (Terminated) |
Adapted from [78]